Gilde invested in Mainstay Medical to support the expansion and enhance clinical evidence of its ReActiv8 neurostimulation therapy for chronic low back pain.

Information on the Target

Mainstay Medical is a notable Irish medical device company that specializes in the development and commercialization of an innovative implantable restorative neurostimulation system known as ReActiv8. This groundbreaking system is designed to alleviate the suffering of individuals experiencing disabling chronic low back pain. The company is actively commercializing its therapeutic solution in various international markets, including the United States, Australia, Germany, and the United Kingdom.

The ReActiv8 therapy focuses on the activation of the multifidus, a crucial stabilizing muscle in the lower back. By strategically placing stimulation electrodes near the medial branch nerves, the system employs an implanted pulse generator to deliver electrical impulses during 30-minute sessions, twice daily. This approach aims to effectively mitigate chronic low back pain and improve the quality of life for patients.

Industry Overview in the Target’s Specific Country

The medical device industry in Ireland is experiencing significant growth, driven by strong research and development capabilities, as well as a supportive regulatory environment. As a hub for many global medical technology comp